Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Delays in Multiple Sclerosis diagnosis (DIMES): protocol for a multicentre, observational study of multiple sclerosis diagnostic pathways in the United Kingdom and Republic of Ireland.
Kuri A, Henshall DE, Chaudhry D, Ooi SZY, Zhang Q, Mathews J, Thomson A, Rog D, Hobart J, Dobson R; Neurology and Neurosurgery Interest Group (NANSIG). Kuri A, et al. Among authors: rog d. BMC Neurol. 2024 Mar 28;24(1):105. doi: 10.1186/s12883-024-03598-z. BMC Neurol. 2024. PMID: 38539132 Free PMC article.
Olfaction: a review.
Jones N, Rog D. Jones N, et al. Among authors: rog d. J Laryngol Otol. 1998 Jan;112(1):11-24. doi: 10.1017/s0022215100139829. J Laryngol Otol. 1998. PMID: 9538440 Review. No abstract available.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Validating the portal population of the United Kingdom Multiple Sclerosis Register.
Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H, Griffiths D, Noble DG, Jones KH, Al-Din A, Craner M, Evangelou N, Harman P, Harrower T, Hobart J, Husseyin H, Kasti M, Kipps C, McDonnell G, Owen C, Pearson O, Rashid W, Wilson H, Ford DV. Middleton RM, et al. Among authors: rog d. Mult Scler Relat Disord. 2018 Aug;24:3-10. doi: 10.1016/j.msard.2018.05.015. Epub 2018 May 25. Mult Scler Relat Disord. 2018. PMID: 29860199
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
Evangelou N, Garjani A, dasNair R, Hunter R, Tuite-Dalton KA, Craig EM, Rodgers WJ, Coles A, Dobson R, Duddy M, Ford DV, Hughes S, Pearson O, Middleton LA, Rog D, Tallantyre EC, Friede T, Middleton RM, Nicholas R. Evangelou N, et al. Among authors: rog d. J Neurol Neurosurg Psychiatry. 2020 Aug 27;92(1):107-9. doi: 10.1136/jnnp-2020-324449. Online ahead of print. J Neurol Neurosurg Psychiatry. 2020. PMID: 32855290 Free PMC article. No abstract available.
A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test.
Middleton RM, Pearson OR, Ingram G, Craig EM, Rodgers WJ, Downing-Wood H, Hill J, Tuite-Dalton K, Roberts C, Watson L, Ford DV, Nicholas R; UK MS Register Research Group. Middleton RM, et al. J Med Internet Res. 2020 Sep 23;22(9):e18234. doi: 10.2196/18234. J Med Internet Res. 2020. PMID: 32965240 Free PMC article.
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.
Garjani A, Middleton RM, Hunter R, Tuite-Dalton KA, Coles A, Dobson R, Duddy M, Hughes S, Pearson OR, Rog D, Tallantyre EC, das Nair R, Nicholas R, Evangelou N. Garjani A, et al. Among authors: rog d. Mult Scler Relat Disord. 2021 Jul;52:102939. doi: 10.1016/j.msard.2021.102939. Epub 2021 May 5. Mult Scler Relat Disord. 2021. PMID: 34010764 Free PMC article.
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
Garjani A, Hunter R, Law GR, Middleton RM, Tuite-Dalton KA, Dobson R, Ford DV, Hughes S, Pearson OR, Rog D, Tallantyre EC, Nicholas R, Morriss R, Evangelou N, das Nair R. Garjani A, et al. Among authors: rog d. Mult Scler. 2022 Jun;28(7):1060-1071. doi: 10.1177/13524585211020435. Epub 2021 Jun 3. Mult Scler. 2022. PMID: 34080892
88 results